ATE226827T1 - Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid - Google Patents

Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid

Info

Publication number
ATE226827T1
ATE226827T1 AT94913464T AT94913464T ATE226827T1 AT E226827 T1 ATE226827 T1 AT E226827T1 AT 94913464 T AT94913464 T AT 94913464T AT 94913464 T AT94913464 T AT 94913464T AT E226827 T1 ATE226827 T1 AT E226827T1
Authority
AT
Austria
Prior art keywords
hyaluronic acid
angiogenesis
pharmaceutical composition
nsaid
fight
Prior art date
Application number
AT94913464T
Other languages
English (en)
Inventor
Derek A Willoughby
S Hospital Bartholomew
Chandan Alam
Hospital
Samuel Simon Asculai
Rudolf Edgar Falk
David William Harper
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE226827T1 publication Critical patent/ATE226827T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Filters For Electric Vacuum Cleaners (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cephalosporin Compounds (AREA)
AT94913464T 1993-04-16 1994-04-15 Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid ATE226827T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002094203A CA2094203A1 (en) 1993-04-16 1993-04-16 Inhibition of angiogenesis
PCT/CA1994/000207 WO1994023725A1 (en) 1993-04-16 1994-04-15 Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid
CN94192096A CN1123005A (zh) 1993-04-16 1994-04-15 用于抑制、控制和消退血管生成的含有透明质酸和nsaid的组合物

Publications (1)

Publication Number Publication Date
ATE226827T1 true ATE226827T1 (de) 2002-11-15

Family

ID=37089291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913464T ATE226827T1 (de) 1993-04-16 1994-04-15 Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid

Country Status (18)

Country Link
EP (1) EP0695187B1 (de)
JP (1) JPH08508505A (de)
CN (1) CN1123005A (de)
AT (1) ATE226827T1 (de)
AU (2) AU694113B2 (de)
BR (1) BR9405781A (de)
CA (1) CA2094203A1 (de)
CZ (1) CZ267995A3 (de)
DE (1) DE69431623D1 (de)
FI (1) FI954914A (de)
HU (2) HUT74462A (de)
IL (1) IL109293A (de)
NO (1) NO954073L (de)
PL (1) PL306806A1 (de)
SG (1) SG48924A1 (de)
SK (1) SK126595A3 (de)
WO (1) WO1994023725A1 (de)
ZA (1) ZA942597B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
DE69734290T2 (de) * 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
WO1998042329A1 (fr) * 1997-03-21 1998-10-01 Mitsubishi Chemical Corporation Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
JP4587148B2 (ja) * 2000-03-24 2010-11-24 生化学工業株式会社 平滑筋細胞増殖促進剤
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
ITPD20020003A1 (it) * 2002-01-11 2003-07-11 Fidia Advanced Biopolymers Srl Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
WO2008145149A1 (en) * 2007-05-28 2008-12-04 Vincenzo Massimo Lombardo Antiphlogistic and analgesic composition for topical use in a region of an animal locomotive system
EP2567697A1 (de) * 2011-09-12 2013-03-13 Almirall, S.A. Topische pharmazeutische Zusammensetzungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids

Also Published As

Publication number Publication date
HU9500113D0 (en) 1995-03-28
SG48924A1 (en) 1998-05-18
AU6994198A (en) 1998-07-23
CZ267995A3 (en) 1996-10-16
JPH08508505A (ja) 1996-09-10
HUT74462A (en) 1996-12-30
HU211954A9 (en) 1996-01-29
FI954914A (fi) 1995-11-06
PL306806A1 (en) 1995-04-18
WO1994023725A1 (en) 1994-10-27
CA2094203A1 (en) 1994-10-17
FI954914A0 (fi) 1995-10-16
ZA942597B (en) 1995-02-08
CN1123005A (zh) 1996-05-22
DE69431623D1 (de) 2002-12-05
IL109293A0 (en) 1994-07-31
BR9405781A (pt) 1996-01-16
SK126595A3 (en) 1997-03-05
IL109293A (en) 1999-01-26
EP0695187B1 (de) 2002-10-30
NO954073D0 (no) 1995-10-13
AU6561694A (en) 1994-11-08
NO954073L (no) 1995-12-04
EP0695187A1 (de) 1996-02-07
AU694113B2 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
ATE226827T1 (de) Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
DK0682514T3 (da) Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
IE41374B1 (en) A composition for treating schizophrenia
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
ES2100222T3 (es) Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
FI102964B1 (fi) Terapeuttisia yhdisteitä
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
DE69334068D1 (de) Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
BR0313411A (pt) Uso de reboxetina para o tratamento de ondas de calor
ATE245447T1 (de) Inhibitor von gehirnödemen
BR0008603A (pt) Método para tratamento de copd
PL371264A1 (en) Method for the treatment of bone disorders
US4575506A (en) Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
AR009446A1 (es) Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.
EP0384302A3 (de) Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms
ES2157258T3 (es) Inhibidores de la reincorporacion de dopamina destinados para el tratamiento del sindrome de parkinson.
RU95122162A (ru) Композиции для ингибирования, регуляции и регрессии ангиогенеза, содержащие гиалуроновую кислоту и nsaid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties